NCT07341009 Evaluation of a Neuropsychological Tool to Assess Temporal Processing Abilities in Alzheimer's Disease
| NCT ID | NCT07341009 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Caen |
| Condition | Alzheimer's Disease (AD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-12-30 |
| Primary Completion | 2027-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2025-12-30 with a primary completion date of 2027-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Perceiving and representing the passage of time allows us to temporally organize perceptions and memories for the coordination of actions, planning, and the mobilization of cognitive processes toward a goal. This innovative project aims to clarify the profile of time impairment associated with normal aging and the progression of age-related pathologies. This project proposes to develop a new neuropsychological tool for quantifying and preventing changes in the relationship to time associated with Alzheimer's disease. Four aspects of time are distinguished, which are measured separately and distributed along a continuum between perception and memory: (a) perception of simultaneity and order; (b) processing of durations; (c) subjective sense of the passage of time; and (d) mental time travel. Crucially, many neurological and psychiatric disorders are associated with impairment in one or more aspects of time. However, time remains largely unexplored in clinical practice. Patients with Alzheimer's disease will complete the CHRONOS battery. This battery allows for a rapid assessment (approximately ten minutes) of the four aspects of time. This new battery will enable the identification of behavioral markers aimed at improving prognosis and prevention regarding individual cognitive trajectories of aging. The relationship to time is closely linked to each person's personal experience. This project will help to put into words difficulties that are not always expressed in terms of time. Thus, considering these pathologies from the perspective of time aims to better understand and prevent their difficulties and to guide the identification of new markers and new avenues for remediation.
Eligibility Criteria
Inclusion Criteria: * No objection from the participant or their legal representative, if applicable, prior to or during the assessment * Deficit in at least two cognitive functions, including episodic memory. Exclusion Criteria: * History of head trauma with loss of consciousness lasting more than 1 hour * Presence of clinically significant major psychiatric disorders (according to DSM-IV-TR criteria) * Use of medications likely to alter cognitive and/or brain function (decision by the principal investigator)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07341009 clinical trial?
This trial is open to participants of all sexes, studying Alzheimer's Disease (AD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07341009 currently recruiting?
Yes, NCT07341009 is actively recruiting participants. Contact the research team at hebert-maria@chu-caen.fr for enrollment information.
Where is the NCT07341009 trial being conducted?
This trial is being conducted at Caen, France.
Who is sponsoring the NCT07341009 clinical trial?
NCT07341009 is sponsored by University Hospital, Caen. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.